Bristol Myers Squibb Reports Phase 3 CheckMate-238 Results for Adjuvant Opdivo in Melanoma

Bristol Myers Squibb today announced results from the Phase 3 CheckMate-238 trial evaluating adjuvant Opdivo (nivolumab) versus ipilimumab in patients with resected stage IIIB-IV melanoma. The trial met its primary endpoint, demonstrating a significant improvement in recurrence-free survival with Opdivo, with a 35% reduction in the risk of disease recurrence or death. These results led to FDA approval of Opdivo as adjuvant therapy for resected melanoma.